SCHEMBL25367171

SCHEMBL25367171

CS(=O)(=O)[C@@H]1C[C@@H](C(=O)O)N(C(=O)O)C1

nearest known ligand 0.42

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.42
AGTR2 P50052 4/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18498478 0.81 ATM (0.38) ATMAGTR2
SCHEMBL26115388 0.80 ATM (0.37) ATMAGTR2
SCHEMBL696186 0.79 HSD17B10 (0.42) ATM
SCHEMBL23925765 0.79 HSD17B10 (0.42) ATM
SCHEMBL23925766 0.79 HSD17B10 (0.42) ATM
SCHEMBL3070231 0.76 CTSS (0.42)
SCHEMBL21806913 0.75 POLB (0.31)
SCHEMBL22029854 0.74 ATM (0.44) ATMAGTR2
SCHEMBL6276413 0.74 ATM (0.44) ATMAGTR2
SCHEMBL6270654 0.74 ATM (0.44) ATMAGTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023183405-A2 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2023-09-28 WO disclosed
EP-4216946-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Achillion Pharmaceuticals, Inc. (US) 2023-08-02 EP disclosed